Peripheral nerve involvement and severity of motor disorder in Parkinson\'s disease: a correlational study

Chovancová, Zuzana; Kaňovský, Petr; Dufek, Jaroslav; Nevrlý, Martin; Otruba, Pavel

doi:10.5507/bp.2009.010

Cited by 9 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AEs potentially associated with levodopa did not occur with increased incidence in the LCIG-naïve group during LCIG initiation. Rates of neuropathy were consistent with background rates in PD patients on levodopa [11,22,23]; there were no cases of Guillain-Barré syndrome. The observed decreases in vitamin B6 were mild to moderate in severity and similar to previously reported values for both LCIG-treated and oral levodopa-treated PD patients [10,14].…”

Section: Discussionsupporting

confidence: 69%

Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients

Slevin

Fernández

Zadikoff

et al. 2015

Journal of Parkinson's Disease

126

View full text Add to dashboard Cite

Background: Levodopa-carbidopa intestinal gel (LCIG) is delivered continuously via intrajejunal percutaneous gastrostomy tube. Objective: To examine long-term safety, efficacy and quality of life of LCIG in an open-label extension study. Methods: Patients received 52 weeks of open-label LCIG treatment following a 12-week double-blind, double-dummy trial in which they were randomized to either LCIG or immediate-release oral levodopa-carbidopa. Patient cohort designation was by receipt of LCIG in the preceding trial randomization (continuing-LCIG vs. LCIG-naïve patients). Results: Sixty-two of 66 subjects in the double-blind proceeded to the open-label extension. Most subjects (95%) reported ≥1 adverse event (AE); only 3 subjects (4.8%) discontinued due to AEs. AE incidence declined gradually over 52 weeks. Serious AEs were reported by 23%. LCIG-naïve patients (N = 29) showed a decrease in "Off" time and an increase in "On" time without troublesome dyskinesia (change from baseline to final visit in mean [SD] hours = −2.34 [2.78] P < 0.001 and 2.19 [3.70] P = 0.005, respectively), while continuing-LCIG patients (N = 33) showed sustained "Off" time duration and further improvement in "On" time without troublesome dyskinesia (−0.42 [2.67] P = 0.377 and 1.00 [2.58] P = 0.036, respectively). The majority of patients in both groups (LCIG-naïve, continuing-LCIG, respectively) were rated 'Much Improved' or 'Very Much Improved' at final visit on the Clinical Global Impression-Improvement scale (69.0%, 69.7%). Conclusions: Continuing-LCIG patients continued to derive benefit from LCIG while the magnitude of improvement among LCIG-naïve patients was similar to that observed for patients on LCIG in the preceding double-blind study. The overall AE profile was consistent with previous phase 3 clinical trials involving the LCIG system.

show abstract

Section: Discussionsupporting

confidence: 69%

Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients

Slevin

Fernández

Zadikoff

et al. 2015

Journal of Parkinson's Disease

126

View full text Add to dashboard Cite

show abstract

“…The external anal sphincter EMG may detect abnormalities in MSA patients [28] but it is clear that it could not be a useful diagnostic tool because anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson disease [29]. Unfortunately, only a few EMG studies were performed in patients with Parkinson disease, yielding no clear conclusions [30].…”

Section: Discussionmentioning

confidence: 98%

Is peripheral neuron degeneration involved in multiple system atrophy? A clinical and electrophysiological study

Gaweł

Jamrozik

Szmidt-Salkowska

et al. 2012

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…The prevalence of peripheral neuropathy in patients with PD ranges from 37.8 to 55% [ 34 , 35 ], which is greater than that among age-matched controls [ 40 ]. Patients with PD have a high prevalence of symmetrical neuropathy, predominantly in sensory axons [ 36 ]. The risk of polyneuropathy has been reported to be increased in patients taking high doses of levodopa [ 37 , 38 ].…”

Section: Classification Of Pain In Pdmentioning

confidence: 99%

An overview of pain in Parkinson's disease

Tai

Lin

2020

Clinical Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Pain is a common non-motor symptom of Parkinson's disease (PD) and the prevalence of pain among PD patients varies because of the disease stage, co-morbidities, and evaluating tools. Risk factors for pain in PD include an early age of onset, long disease duration, motor complications, concomitant depressive symptoms, female gender, and associated medical conditions. In patients with PD, pain can be classified as musculoskeletal pain, chronic body pain (central or visceral), fluctuation-related pain, nocturnal pain, orofacial pain, pain with discolouration/oedema/swelling, and radicular/neuropathic pain; musculoskeletal pain as the most common type. Potential underlying mechanisms include a disruption of peripheral nociception and alterations in central pain threshold/processing. Genetic polymorphisms in genes that confer pain susceptibility might also play a role in the occurrence of pain in PD. In advanced stage of patients with PD, polyneuropathy could occur in patients using high dosage of levodopa. Pain often correlates to other non-motor symptoms of PD, including depression, sleep, and autonomic symptoms. Dopaminergic drugs, non-dopaminergic medications, botulinum toxin, deep brain stimulation, and physiotherapy have shown some benefits for certain types of PD-related pain. An increased awareness of pain as a common non-motor symptom of PD provides further insights into sensory system dysregulation in this disease. In this review, we aim to summarizes the clinical features of pain in patients with PD and emphasize the latest evidence of pain related to levodopa treatment.

show abstract

Peripheral nerve involvement and severity of motor disorder in Parkinson\'s disease: a correlational study

Cited by 9 publications

References 15 publications

Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients

Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients

Is peripheral neuron degeneration involved in multiple system atrophy? A clinical and electrophysiological study

An overview of pain in Parkinson's disease

Contact Info

Product

Resources

About